Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a successful intracellular pathogen that is responsible for the highest mortality rate among diseases caused by bacterial infections.
During early interaction with the host innate cells, M. tuberculosis cell surface antigens interact with Toll like receptor 4 (TLR4) to activate the nucleotide-binding domain, leucine-rich-repeat containing family, pyrin domain-containing 3 (NLRP3) canonical, and non-canonical inflammasome pathways.
NLRP3 inflammasome activation in the alveoli has been reported to contribute to the early inflammatory response that is needed for an effective anti-TB response through production of pro-inflammatory cytokines, including those of the Interleukin 1 (IL1) family.
However, overstimulation of the alveolar NLRP3 inflammasomes can induce excessive inflammation that is pathological to the host. Several studies have explored the use of medicinal plants and/or their active derivatives to inhibit excessive stimulation of the inflammasomes and its associated factors, thus reducing immunopathological response in the host.
This review describes the molecular mechanism of the NLRP3 inflammasome activation in the alveoli during M. tuberculosis infection.
Furthermore, the mechanisms of inflammasome inhibition using medicinal plant and their derivatives will also be explored, thus offering a novel perspective on the alternative control strategies of M. tuberculosis-induced immunopathology.
Adjunct n-3 Long-Chain Polyunsaturated Fatty Acid Treatment in Tuberculosis Reduces Inflammation and Improves Anemia of Infection More in C3HeB/FeJ Mice With Low n-3 Fatty Acid Status Than Sufficient n-3 Fatty Acid Status
Populations at risk for tuberculosis (TB) may have a low n-3 polyunsaturated fatty acid (PUFA) status. Our research previously showed that post-infection supplementation of n-3 long-chain PUFA (LCPUFA) in TB without TB medication was beneficial in n-3 PUFA sufficient but not in low-status C3HeB/FeJ mice.
In this study, we investigated the effect of n-3 LCPUFA adjunct to TB medication in TB mice with a low compared to a sufficient n-3 PUFA status. Mice were conditioned on an n-3 PUFA-deficient (n-3FAD) or n-3 PUFA-sufficient (n-3FAS) diet for 6 weeks before TB infection.
Post-infection at 2 weeks, both groups were switched to an n-3 LCPUFA [eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA)] supplemented diet and euthanized at 4- and 14- days post-treatment. Iron and anemia status, bacterial loads, lung pathology, lung cytokines/chemokines, and lung lipid mediators were measured.
Following 14 days of treatment, hemoglobin (Hb) was higher in the n-3FAD than the untreated n-3FAS group (p = 0.022), whereas the n-3FAS (drug) treated control and n-3FAS groups were not.
Pro-inflammatory lung cytokines; interleukin-6 (IL-6) (p = 0.011), IL-1α (p = 0.039), MCP1 (p = 0.003), MIP1- α (p = 0.043), and RANTES (p = 0.034); were lower, and the anti-inflammatory cytokine IL-4 (p = 0.002) and growth factor GMCSF (p = 0.007) were higher in the n-3FAD compared with the n-3FAS mice after 14 days.
These results suggest that n-3 LCPUFA therapy in TB-infected mice, in combination with TB medication, may improve anemia of infection more in low n-3 fatty acid status than sufficient status mice.
Furthermore, the low n-3 fatty acid status TB mice supplemented with n-3 LCPUFA showed comparatively lower cytokine-mediated inflammation despite presenting with lower pro-resolving lipid mediators.
Childhood Tuberculosis: An Under Prioritized Disease in Nepal
Globally, childhood tuberculosis constitutes up to 10% of overall tuberculosis cases. In Nepal, childhood tuberculosis has remained around 5.5% of overall tuberculosis cases and has remained stagnant over the years.
Moreover, our health system is focused on adult tuberculosis. Childhood tuberculosis has recently got its attention both at the national and international levels.
National Tuberculosis Program has been a successful program; however, more has to be done to track childhood tuberculosis progress. In this viewpoint, we discuss current initiatives taken by the government and the way forward for case detection and management of childhood tuberculosis in Nepal.
Analysis of the application of a gene chip method for detecting Mycobacterium tuberculosis drug resistance in clinical specimens: a retrospective study
Most Mycobacterium tuberculosis (Mtb) resistant to rifampicin (RIF) has mutations in the rpoB gene, while most Mtb resistant to isoniazid (INH) has mutations in the katG gene or inhA promoter.
We used gene chip technology to detect mutations in these genes to determine the resistance of Mtb to RIF and INH. A total of 4148 clinical specimens with sputum smear positivity for acid-fast bacilli (AFB) were detected.
Then, taking the results of the drug sensitivity test (DST) as the reference standard, the detection efficiency of sputum samples from different grades of positive smears was compared in detail.
We found that the sensitivity of the gene chip method for detecting sputum samples with a grade ≥ AFB 2 + was higher than that of sputum samples with a grade ≤ AFB 1 + (P < 0.05).
When the grade of the sample was ≤ AFB 1 +, the sensitivity of the gene chip method was 72.6% for RIF, 67.3% for INH, and 60.0% for MDR-TB. When the grade of the sample was ≥ AFB 2 +, the sensitivity of the gene chip method was 84.5% for RIF, 78.2% for INH, and 73.9% for MDR-TB.
The results show that gene chip technology can be directly used to diagnose drug-resistant tuberculosis in clinical specimens, and the diagnostic efficiency for the detection of sputum specimens with a grade ≥ AFB 2 + is better than that of other sputum specimens.
Early phase of effective treatment induces distinct transcriptional changes in Mycobacterium tuberculosis expelled by pulmonary tuberculosis patients
Effective treatment reduces a tuberculosis patient’s ability to infect others even before they test negative in sputum or culture. Currently, the basis of reduced infectiousness of the Mycobacterium tuberculosis (Mtb) with effective treatment is unclear.
We evaluated changes in aerosolized bacteria expelled by patients through a transcriptomic approach before and after treatment initiation (up to 14 days) by RNA sequencing. A distinct change in the overall transcriptional profile was seen post-treatment initiation compared to pretreatment, only when patients received effective treatment.
This also led to the downregulation of genes associated with cellular activities, cell wall assembly, virulence factors indicating loss of pathogenicity, and a diminished ability to infect and survive in new host cells. Based on this, we identified genes whose expression levels changed with effective treatment.
) Mycobacterium tuberculosis 16kD (M. tuberculosis) |
|
MBS6009340-1mg |
MyBiosource |
1(mg |
EUR 885 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
|
MBS6009340-5x1mg |
MyBiosource |
5x1mg |
EUR 3830 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
|
MBS6011625-1mg |
MyBiosource |
1(mg |
EUR 1295 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
|
MBS6011625-5x1mg |
MyBiosource |
5x1mg |
EUR 5675 |
 M. tuberculosis |
|
5172 |
Virostat |
100 ug |
EUR 270 |
|
Description: CFP10 |
M. tuberculosis |
|
5175 |
Virostat |
100 ug |
EUR 270 |
|
Description: 16 kDa |
M. tuberculosis |
|
5176 |
Virostat |
100 ug |
EUR 270 |
|
Description: 16 kDa |
M. tuberculosis |
|
5177 |
Virostat |
100 ug |
EUR 270 |
|
Description: Hsp65 |
M. tuberculosis |
|
5178 |
Virostat |
100 ug |
EUR 270 |
|
Description: Hsp65 |
M. tuberculosis |
|
8811 |
Virostat |
100 ug |
EUR 340 |
|
Description: 38 kDa |
M. tuberculosis |
|
4601 |
Virostat |
1 ml |
EUR 235 |
|
|
|
Description: all antigens |
 Antibody) Mycobacterium tuberculosis (M. tuberculosis) Antibody |
|
abx415707-1ml |
Abbexa |
1 ml |
EUR 727.2 |
|
|
Mycobacterium tuberculosis (M. tuberculosis) Antibody |
|
abx415707-200l |
Abbexa |
200 µl |
EUR 537.5 |
 M. Tuberculosis HSP70 Protein |
|
abx060544-100ug |
Abbexa |
100 ug |
EUR 1378.8 |
|
|
 Mycobacterium tuberculosis, HSP, Recombinant |
|
MBS636978-01mg |
MyBiosource |
0.1mg |
EUR 735 |
Mycobacterium tuberculosis, HSP, Recombinant |
|
MBS636978-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3165 |
 (PE)) Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
|
MBS6129466-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
|
MBS6129466-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
|
MBS6129467-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
|
MBS6129467-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
 (AP)) Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
|
MBS6126370-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
|
MBS6126370-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
|
MBS6126371-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
|
MBS6126371-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
 (HRP)) Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
|
MBS6128846-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
|
MBS6128846-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
|
MBS6128847-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
|
MBS6128847-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
 (APC)) Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
|
MBS6126990-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
|
MBS6126990-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
|
MBS6126991-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
|
MBS6126991-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
 (FITC)) Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
|
MBS6128225-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
|
MBS6128225-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
|
MBS6128226-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
|
MBS6128226-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
 Recombinant M. Tuberculosis HSP65 |
|
DAGA-194 |
Creative Diagnostics |
0.1 mg |
Ask for price |
|
|
|
Description: Recombinant |
 (Biotin)) Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
|
MBS6127611-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
|
MBS6127611-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
|
MBS6127612-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
|
MBS6127612-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
 Recombinant Mycobacterium Tuberculosis HSP Protein |
|
VAng-Yyj0063-10g |
Creative Biolabs |
10 µg |
EUR 2250 |
|
Description: Mycobacterium Tuberculosis, HSP, recombinant protein. |
 MAb to M. tuberculosis |
|
MBS310270-1mg |
MyBiosource |
1mg |
EUR 955 |
MAb to M. tuberculosis |
|
MBS310270-5x1mg |
MyBiosource |
5x1mg |
EUR 4115 |
MAb to M. tuberculosis |
|
MBS310271-1mg |
MyBiosource |
1mg |
EUR 1035 |
MAb to M. tuberculosis |
|
MBS310271-5x1mg |
MyBiosource |
5x1mg |
EUR 4485 |
MAb to M. tuberculosis |
|
MBS310272-1mg |
MyBiosource |
1mg |
EUR 1035 |
MAb to M. tuberculosis |
|
MBS310272-5x1mg |
MyBiosource |
5x1mg |
EUR 4485 |
MAb to M. tuberculosis |
|
MBS310273-1mg |
MyBiosource |
1mg |
EUR 1035 |
MAb to M. tuberculosis |
|
MBS310273-5x1mg |
MyBiosource |
5x1mg |
EUR 4485 |
 Rabbit A' M. tuberculosis |
|
MBS315160-1mL |
MyBiosource |
1mL |
EUR 855 |
Rabbit A' M. tuberculosis |
|
MBS315160-5x1mL |
MyBiosource |
5x1mL |
EUR 3685 |
Rabbit A' M. tuberculosis |
|
MBS315161-1mL |
MyBiosource |
1mL |
EUR 915 |
Rabbit A' M. tuberculosis |
|
MBS315161-5x1mL |
MyBiosource |
5x1mL |
EUR 3945 |
Rabbit A' M. tuberculosis |
|
MBS315162-1mL |
MyBiosource |
1mL |
EUR 915 |
Rabbit A' M. tuberculosis |
|
MBS315162-5x1mL |
MyBiosource |
5x1mL |
EUR 3945 |
Rabbit A' M. tuberculosis |
|
MBS315163-1mL |
MyBiosource |
1mL |
EUR 800 |
Rabbit A' M. tuberculosis |
|
MBS315163-5x1mL |
MyBiosource |
5x1mL |
EUR 3420 |
 IgG) Monoclonal Anti-M. tuberculosis Heat Shock Protein 70 (hsp70/Dnak/ML2496) IgG |
|
HSP701-M |
Alpha Diagnostics |
100 ul |
EUR 578.4 |
 M. Tuberculosis TB22.2 Antigen |
|
DAGA-186 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. tuberculosis CFP10, Recomb. |
|
MBS319838-01mg |
MyBiosource |
0.1mg |
EUR 755 |
M. tuberculosis CFP10, Recomb. |
|
MBS319838-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3165 |
 M. tuberculosis Moex protein |
|
MBS596054-1mg |
MyBiosource |
1mg |
EUR 425 |
M. tuberculosis Moex protein |
|
MBS596054-2mg |
MyBiosource |
2mg |
EUR 700 |
M. tuberculosis Moex protein |
|
MBS596054-5mg |
MyBiosource |
5mg |
EUR 1505 |
 M. Tuberculosis Mpt70 Antigen |
|
DAGA-182 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis MPT83 Antigen |
|
DAGA-183 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis Mpt64 Antigen |
|
DAGA-184 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. tuberculosis CFP10 Protein |
|
abx061400-100g |
Abbexa |
100 µg |
Ask for price |
 M. tuberculosis CFP10, Protein |
|
abx061400-100ug |
Abbexa |
100 ug |
EUR 961.2 |
|
|
M. tuberculosis CFP10 Protein |
|
abx061400-10g |
Abbexa |
10 µg |
EUR 1100 |
M. tuberculosis CFP10 Protein |
|
abx061400-50g |
Abbexa |
50 µg |
Ask for price |
 M. tuberculosis ESAT6, Protein |
|
abx061402-100ug |
Abbexa |
100 ug |
EUR 910.8 |
|
|
 M. Tuberculosis Rv2672 Antigen |
|
DAGA-174 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis Rv2253 Antigen |
|
DAGA-177 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis MT3413 Antigen |
|
DAGA-178 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis Rv0477 Antigen |
|
DAGA-179 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis Rv0192A Antigen |
|
DAGA-173 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis Rv0398c Antigen |
|
DAGA-176 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 Antibody) Mycobacterium tuberculosis 38 kDa Antigen (M. tuberculosis 38 kDa) Antibody |
|
abx411025-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
|
Mycobacterium tuberculosis 38 kDa Antigen (M. tuberculosis 38 kDa) Antibody |
|
abx411025-100g |
Abbexa |
100 µg |
EUR 487.5 |
 Antibody) Mycobacterium tuberculosis 16 kDa Antigen (M. tuberculosis 16 kDa) Antibody |
|
abx415759-01mg |
Abbexa |
0.1 mg |
EUR 760.8 |
|
|
Mycobacterium tuberculosis 16 kDa Antigen (M. tuberculosis 16 kDa) Antibody |
|
abx415759-200l |
Abbexa |
200 µl |
EUR 600 |
 Mab to M. tuberculosis MPT64 |
|
MBS313702-1mg |
MyBiosource |
1mg |
EUR 515 |
Mab to M. tuberculosis MPT64 |
|
MBS313702-5x1mg |
MyBiosource |
5x1mg |
EUR 2135 |
Mab to M. tuberculosis MPT64 |
|
MBS313703-1mg |
MyBiosource |
1mg |
EUR 515 |
Mab to M. tuberculosis MPT64 |
|
MBS313703-5x1mg |
MyBiosource |
5x1mg |
EUR 2135 |
Mab to M. tuberculosis MPT64 |
|
MBS313704-1mg |
MyBiosource |
1mg |
EUR 515 |
Mab to M. tuberculosis MPT64 |
|
MBS313704-5x1mg |
MyBiosource |
5x1mg |
EUR 2135 |
Mab to M. tuberculosis MPT64 |
|
MBS313705-1mg |
MyBiosource |
1mg |
EUR 515 |
Mab to M. tuberculosis MPT64 |
|
MBS313705-5x1mg |
MyBiosource |
5x1mg |
EUR 2135 |
 M. tuberculosis MPT64 Rec. Ag |
|
MBS313721-1mg |
MyBiosource |
1mg |
EUR 515 |
M. tuberculosis MPT64 Rec. Ag |
|
MBS313721-5x1mg |
MyBiosource |
5x1mg |
EUR 2155 |
M. tuberculosis MPT64 Rec. Ag |
|
MBS313722-1mg |
MyBiosource |
1mg |
EUR 515 |
M. tuberculosis MPT64 Rec. Ag |
|
MBS313722-5x1mg |
MyBiosource |
5x1mg |
EUR 2155 |
 MAb to M. tuberculosis, 16kDa |
|
MBS310461-1mg |
MyBiosource |
1mg |
EUR 605 |
MAb to M. tuberculosis, 16kDa |
|
MBS310461-5x1mg |
MyBiosource |
5x1mg |
EUR 2640 |
 MAb to M. tuberculosis, 38kDa |
|
MBS310523-1mg |
MyBiosource |
1mg |
EUR 605 |
MAb to M. tuberculosis, 38kDa |
|
MBS310523-5x1mg |
MyBiosource |
5x1mg |
EUR 2640 |
 MAb to M. tuberculosis CFP10 |
|
MBS312553-1mg |
MyBiosource |
1mg |
EUR 805 |
MAb to M. tuberculosis CFP10 |
|
MBS312553-5x1mg |
MyBiosource |
5x1mg |
EUR 3455 |
MAb to M. tuberculosis CFP10 |
|
MBS312555-1mg |
MyBiosource |
1mg |
EUR 805 |
MAb to M. tuberculosis CFP10 |
|
MBS312555-5x1mg |
MyBiosource |
5x1mg |
EUR 3455 |
 Recombinant M. tuberculosis 38kD |
|
DAG-WT1091 |
Creative Diagnostics |
1 mg |
EUR 480 |
|
|
|
Description: Recombinant |
 M. tuberculosis, 38kDa, Recombinant |
|
MBS319392-01mg |
MyBiosource |
0.1mg |
EUR 1150 |
M. tuberculosis, 38kDa, Recombinant |
|
MBS319392-5x01mg |
MyBiosource |
5x0.1mg |
EUR 4995 |
 M. Tuberculosis 85-C Antigen |
|
DAGA-175 |
Creative Diagnostics |
100 µg |
EUR 749.7 |
|
|
|
Description: Recombinant |
 M. Tuberculosis 85-A Antigen |
|
DAGA-181 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis 85-B Antigen |
|
DAGA-185 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis 48 kDa protein |
|
DAGA-191 |
Creative Diagnostics |
1 mg |
Ask for price |
|
|
|
Description: Recombinant |
 M. Tuberculosis 38 kDa Protein |
|
abx060636-100g |
Abbexa |
100 µg |
Ask for price |
M. Tuberculosis 38 kDa Protein |
|
abx060636-100ug |
Abbexa |
100 ug |
EUR 978 |
|
|
M. Tuberculosis 38 kDa Protein |
|
abx060636-10g |
Abbexa |
10 µg |
EUR 1437.5 |
M. Tuberculosis 38 kDa Protein |
|
abx060636-50g |
Abbexa |
50 µg |
Ask for price |
 M. Tuberculosis 85A Antigen[his] |
|
DAGA-189 |
Creative Diagnostics |
10 µg |
EUR 618.19 |
|
|
|
Description: Recombinant |
 M. Tuberculosis 85A Antigen [His] |
|
DAGA-192 |
Creative Diagnostics |
50 µg |
EUR 834.75 |
|
|
|
Description: Recombinant |
 M. Tuberculosis ESAT-6 Antigen |
|
DAGA-187 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 Purified) Anti-Tb7.7 (M. tuberculosis) Purified |
|
11-190-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 M. Tuberculosis Mpt63/MPB63 Antigen |
|
DAGA-180 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
Anti-Tb7.7 (M. tuberculosis) Purified |
|
MBS1801449-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-Tb7.7 (M. tuberculosis) Purified |
|
MBS1801449-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
 Purified) Anti-Acr1 (M. tuberculosis) Purified |
|
11-185-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 Purified) Anti-Tb10.4 (M. tuberculosis) Purified |
|
11-186-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 Purified) Anti-Tb10.3 (M. tuberculosis) Purified |
|
11-187-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 Purified) Anti-Acr2 (M. tuberculosis) Purified |
|
11-188-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 Purified) Anti-GlcB (M. tuberculosis) Purified |
|
11-192-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 Recombinant M. Tuberculosis CFP-10 |
|
DAGA-170 |
Creative Diagnostics |
1 mg |
EUR 756 |
|
|
|
Description: Recombinant |
Anti-Acr1 (M. tuberculosis) Purified |
|
MBS1801444-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-Acr1 (M. tuberculosis) Purified |
|
MBS1801444-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
Anti-Tb10.4 (M. tuberculosis) Purified |
|
MBS1801445-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-Tb10.4 (M. tuberculosis) Purified |
|
MBS1801445-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
Anti-Tb10.3 (M. tuberculosis) Purified |
|
MBS1801446-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-Tb10.3 (M. tuberculosis) Purified |
|
MBS1801446-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
Anti-Acr2 (M. tuberculosis) Purified |
|
MBS1801447-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-Acr2 (M. tuberculosis) Purified |
|
MBS1801447-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
Anti-GlcB (M. tuberculosis) Purified |
|
MBS1801450-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-GlcB (M. tuberculosis) Purified |
|
MBS1801450-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
 Purified) Anti-Ag85b (M. tuberculosis) Purified |
|
11-189-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
Anti-Ag85b (M. tuberculosis) Purified |
|
MBS1801448-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-Ag85b (M. tuberculosis) Purified |
|
MBS1801448-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
 M. Tuberculosis 63 kDa protein [His] |
|
DAGA-190 |
Creative Diagnostics |
1 mg |
Ask for price |
|
|
|
Description: Recombinant |
) Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70) |
|
MBS638121-01mg |
MyBiosource |
0.1mg |
EUR 1135 |
Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70) |
|
MBS638121-5x01mg |
MyBiosource |
5x0.1mg |
EUR 4960 |
Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70) |
|
MBS637313-0002mg |
MyBiosource |
0.002mg |
EUR 375 |
Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70) |
|
MBS637313-001mg |
MyBiosource |
0.01mg |
EUR 525 |
Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70) |
|
MBS637313-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2210 |
 Zmp1 M. tuberculosis Recombinant Protein |
|
90-361 |
ProSci |
50 ug |
EUR 752.1 |
|
Description: M13 endopeptidases are single-pass, transmembrane zinc-metallopeptidases responsible in human for the regulation of the biological activity of many hormones and peptides and are involved in many important processes such as blood pressure regulation (Neprilysin or NEP1), cardiovascular development (Endothelin Converting Enzyme-1 or ECE-12), prevention of haemolytic reaction (KELL) and phosphate homeostasis (PHEX). Zmp1 is a soluble enzyme member of the M13 endopeptidases family that plays a key role in Mycobacterium tuberculosis pathogenicity with a still unknown mechanism. Recently, it was shown to suppress inflammasome activation by inhibiting caspase-1 activation, thus preventing processing of pro-IL-1beta into IL-1beta and the consequent phagosome maturation. |
 Recombinant M. Tuberculosis Moex antigen |
|
DAGA-213 |
Creative Diagnostics |
1 mg |
Ask for price |
|
|
|
Description: Native |
 (CFP10) Antigen) M. Tuberculosis EsxB (LHP) (CFP10) Antigen |
|
DAGA-188 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
 M. Tuberculosis ClpP Protease Assay Kit |
|
TBP100K |
ProFoldin |
100 assays |
EUR 292.32 |
|
Description: This product includes 3100 ul of Assay Buffer and 310 ul of 10 x Substrate and 3500 ul of Stop solution. It is for 100 assays in 384-well plate format |
 Mouse antibody for M. tuberculosis ESAT6 |
|
5173 |
Virostat |
100 ug |
EUR 386.26 |
|
Description: This is purified Mouse monoclonal antibody against M tuberculosis ESAT6 for WB, ELISA. |
 Mouse antibody for M. tuberculosis 38kDa |
|
5174 |
Virostat |
100 ug |
EUR 386.26 |
|
Description: This is purified Mouse monoclonal antibody against M tuberculosis 38kDa for WB, ELISA. |
 Purified) Anti-CFP-10 (M. tuberculosis) Purified |
|
11-490-C025 |
ExBio |
0.025 mg |
EUR 99 |
Anti-CFP-10 (M. tuberculosis) Purified |
|
11-490-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
 Purified) Anti-ESAT-6 (M. tuberculosis) Purified |
|
11-491-C025 |
ExBio |
0.025 mg |
EUR 99 |
Anti-ESAT-6 (M. tuberculosis) Purified |
|
11-491-C100 |
ExBio |
0.1 mg |
EUR 198 |
|
|
) Recombinant M. tuberculosis CFP10 (No tag) |
|
DAG-WT1769 |
Creative Diagnostics |
1 mg |
EUR 1460 |
|
|
|
Description: Recombinant |
Anti-CFP-10 (M. tuberculosis) Purified |
|
MBS1801463-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-CFP-10 (M. tuberculosis) Purified |
|
MBS1801463-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
Anti-ESAT-6 (M. tuberculosis) Purified |
|
MBS1801464-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Anti-ESAT-6 (M. tuberculosis) Purified |
|
MBS1801464-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1120 |
 Monoclonal antibody to M. tuberculosis CFP |
|
MBS596232-1mg |
MyBiosource |
1mg |
EUR 480 |
Monoclonal antibody to M. tuberculosis CFP |
|
MBS596232-2mg |
MyBiosource |
2mg |
EUR 700 |
Monoclonal antibody to M. tuberculosis CFP |
|
MBS596232-5mg |
MyBiosource |
5mg |
EUR 1505 |
 Antibody) Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (M. tuberculosis inhA) Antibody |
|
abx109426-100l |
Abbexa |
100 µl |
EUR 162.5 |
Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (M. tuberculosis inhA) Antibody |
|
20-abx109426 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
 Antibody) Anti-Mycobacterium tuberculosis, heat shock protein 70 (HSP70) Antibody |
|
Y059575 |
ABM |
100 µg |
EUR 325 |
 control for Western) Recombinant purified M. tuberculosis Heat Shock Protein 70 (hsp70/hsp72/Dnak/ML2496) control for Western |
|
HSP701-C |
Alpha Diagnostics |
100 ul |
EUR 343.2 |
 M. Tuberculosis p60-Related Protein Rv0024 |
|
DAGA-172 |
Creative Diagnostics |
100 µg |
EUR 665.44 |
|
|
|
Description: Recombinant |
The observations of the study open up avenues for further evaluating the changes in bacterial gene expression during the early phase of treatment as biomarkers for monitoring response to tuberculosis treatment regimens and provide means of identifying better correlates of Mtb transmission.
